External Device to Correct Functional Mitral Regurgitation
Technology ID: 05-025
Chronic heart failure is the leading cause of death in humans in Western countries. It has been estimated that congestive heart failure afflicts nearly 4 million Americans, with 500,000 new cases each year. Cardiac transplantation is the only definitive treatment for end stage congestive heart failure. Because of the shortage of organs to transplant, only 2% of patients on the transplant list survive long enough to receive a matching heart. Older patients and diabetic patients are not candidates for heart transplantation.
If functional mitral regurgitation is diagnosed with cardiomyopathy the prognosis is significantly altered. The survival rate can be reduced 20% for patients with cardiomyopathy and mitral regurgitation versus 60% for patients with cardiomyopathy without mitral valve regurgitation.
Thus, there is need for a device that would reduce functional mitral regurgitation by reducing tethering from the papillary muscle without cardiopulmonary bypass and without being in contact with blood. It would then prevent progression of dilated cardiomyopathy into congestive heart failure. Researchers at Colorado State University have developed an external device that would reduce functional mitral regurgitation in patients with diluted cardiomyopathy. This device could be applied around the heart without requiring cardiopulmonary bypass and without being in contact with blood, eliminating the increased risk of thromboembolism.
Inventors: Eric Monnet, Christopher Orton, Susan James, Kyle Ordway